LeonaBio, Inc. (LONA) Stock Price & Analysis
LeonaBio, Inc. (LONA) closed at USD 5.29 on Thursday, October 15, 2026, down 1.86% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 5.39; the Oct 15, 2026 session ranged USD 4.91–5.42 on volume of 35,246 shares. Market capitalization is $49.84M, with a 52-week range of USD 2.21–14.21 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:19 UTC.
Also available as compact Markdown for AI agents: nexqual.com/LONA.md
Key facts (LONA)
- Analysts: Buy (mean 1.50 on a 1–5 scale) (4 analysts), mean target USD 17.33 (range 15–20).
- Total return with dividends: 1Y +44.5% vs S&P 500 +18.1%; 5Y -94.5% vs S&P 500 +85.1%.
- Next earnings: 2026-08-06, EPS estimate USD -0.69, revenue estimate $0K.
Analysts (LONA)
Consensus Buy (mean 1.50 on a 1–5 scale), 4 analysts; mean target USD 17.33 (low 15, high 20).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-19 | Mizuho | Target lowered | Outperform | $16 → $15 |
| 2026-08-17 | Citizens | Target lowered | Market Outperform | $18 → $17 |
| 2026-07-30 | Citizens | Upgrade | Market Perform → Market Outperform | $18 |
Total return (dividends reinvested) (LONA)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | +44.5% | -94.5% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +44.7% | -43.9% |
| Volatility (annualized) | 115.3% | 125.4% |
| Max drawdown | -75.4% (Apr 2026→Sep 2026) | -98.5% (Nov 2021→Apr 2025) |
Key Statistics (as of October 16, 2026 at 05:19 UTC)
| Price | USD 5.29 |
|---|---|
| Change | ▼ 1.86% (down) |
| Previous Close | USD 5.39 |
| Open | USD 5.41 |
| Day Range | USD 4.91 – 5.42 |
| 52-Week Range | USD 2.21 – 14.21 |
| Volume | 35,246 shares |
| Market Cap | $49.84M |
| Exchange | NCM |
Technical Analysis (LONA)
Nexqual's technical model rates LONA "SELL" based on 1 bullish and 4 bearish signals across 127 daily candles, as of October 16, 2026 at 05:19 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 43.75 (neutral) |
| vs SMA50 | Below (USD 6.66) |
| MACD | -0.25 (negative) |
Analyst Ratings (LONA)
Wall Street analysts rate LONA "Buy" based on 4 analysts, with a mean price target of USD 17.33 (range USD 15–20), per Nexqual as of October 16, 2026 at 05:19 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 17.33 |
| High Target | USD 20 |
| Low Target | USD 15 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (LONA)
| Next Earnings Date | 2026-08-06 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.8 vs est -1.36 ▲ beat |
| 2026-03-31 | USD -1.73 vs est -2.5 ▲ beat |
| 2025-12-31 | USD -18.92 vs est -1.27 ▼ miss |
| 2025-09-30 | USD -1.68 vs est -1.22 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financials & Fundamentals (LONA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -431.39% |
| Debt / Equity | 0.02 |
| Current Ratio | 7.01 |
| Total Cash | $51.07M |
| Total Debt | $577,000 |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financial Health Score (LONA)
Nexqual rates LeonaBio, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:19 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $51M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$62M (TTM) |
| Efficiency | Critical — ROE -431%, ROA -74.1% |
Ownership (LONA)
| Insider Ownership | +4.07% |
|---|---|
| Institutional Ownership | +87.66% |
| Shares Outstanding | 9.42M |
| Float | 4.73M |
| Short % of Float | +0.26% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Leadership (LONA)
LeonaBio, Inc. is led by Mark J. Litton (age 57), President, CEO & Director, per Nexqual as of October 16, 2026 at 05:19 UTC.
| President, CEO & Director | Mark J. Litton (age 57) |
|---|---|
| Chief Financial Officer | Robert Renninger (age 40) |
| Chief Scientific Officer | Kevin Church (age 40) |
Major Backers & Investors (LONA)
Notable institutional backers of LeonaBio, Inc. include Perceptive Advisors Llc, Adar1 Capital Management, LLC , Acorn Capital Advisors, LLC , according to Nexqual as of October 16, 2026 at 05:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Perceptive Advisors Llc | 19.79% |
| Adar1 Capital Management, LLC | 8.27% |
| Acorn Capital Advisors, LLC | 6.76% |
| Commodore Capital Lp | 4.94% |
| NEA Management Company, LLC | 4.94% |
| TCG Crossover Management, LLC | 4.94% |
| Spruce Street Capital LP | 4.19% |
| Kalehua Capital Management LLC | 4.19% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:19 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt